These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30028343)

  • 1. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
    Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
    Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
    Douros A; Rouette J; Yin H; Yu OHY; Filion KB; Azoulay L
    Diabetes Care; 2019 Aug; 42(8):1496-1503. PubMed ID: 31182489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
    Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
    JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OHY; Renoux C; Bitton A; Azoulay L
    BMJ; 2018 Mar; 360():k872. PubMed ID: 29563098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
    Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
    Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
    Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
    Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk.
    Wang M; Li M; Xie Y
    Endocr J; 2021 Jun; 68(6):729-738. PubMed ID: 33642418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
    BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
    Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
    Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
    Faillie JL; Filion KB; Patenaude V; Ernst P; Azoulay L
    Diabetes Obes Metab; 2015 Apr; 17(4):379-85. PubMed ID: 25581902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
    Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
    Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Shapiro SB; Yin H; Yu OHY; Azoulay L
    Drug Saf; 2024 Aug; 47(8):759-769. PubMed ID: 38720114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
    JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.